

2008 Corporate Citizenship Report

GRI Content Index



Consideration was given to the Global Reporting Initiative Sustainability Reporting Guidelines (G3) in preparing the Wyeth Corporate Citizenship Report 2008. This index contains references to G3 indicators, but we do not declare a reporting level at this time. GRI Indicators that are not reported mean that the information is not collected on a global basis, that the information is kept confidential for competitive or other reasons, or that we were not able to address the topic for the current report but may address it in future reports.

Keyword	G3 Reference	Page(s) in Report
Access to health care	EC8	10-13, 17-18, 19, 20-21, 47
Accident rates	LA7	36, 52
Advertising	PR6	46
Alzheimer's disease		6
Animal welfare	DMA-Society	49
Awards and recognition	2.10	9, 16, 19, 24, 39
Benefits, employees	LA3, LA8	23
Business conduct policy	SO2-4	44-46
Business segments	2.2, 2.3, 2.5, 2.7	2
Carbon dioxide emissions	EN16	31-32, 52
Chairman's message	1.1	1
Challenges/key issues	1.2	3
Children's health		14-15
Climate change	EC2, EN16, EN18	31-32
Clinical trials	PR1	48
Code of Conduct	4.8	44-45
Community health	SO1	14, 17-19, 21
Commuter Assistance	EN29	36
Compliance, corporate	4.9	43
Contributions, charitable	EC1	14, 16-18, 45
Corporate governance	4.1	43, 44
Corporate profile	2.1-2.8	2
Customers	4.14	2
Disaster relief		17-18
Diversity & inclusion, employees		26-29
Diversity, supplier	EC6	28
Drug importation		48
Economic performance	EC1	2
Employee assistance	LA8	23
Employee health/wellness	LA3, LA8	23
Energy use	EN3-6	32
Environmental awareness	DMA-Environment	35, 36
Environmental management	DMA-Environment	31-36
External certifications	DMA-Environmental	37-38

Keyword	G3 Reference	Page(s) in Report
Fleet safety		38-39
Green chemistry	PR1, EN26	34
Greenhouse gases	EN16, 18	31-32, 52
Intellectual property	DMA-Society	48
ISO 14001	EMA-Environment	38
Lost-time injury	LA7	36, 52
Marketing	PR6	46
Mission, vision, values		IBC
Net sales	2.8, EC1	2
Organizational profile	2.1-2.10	2
Ozone-depleting emissions	EN19	38, 52
Packaging	EN1, EN26	35
Partnerships, R&D		7-8
Patient awareness/education		50
Pharmaceuticals in the environment	EN26	34
Pneumococcal disease		10
Political contributions	SO5	46-47
Products	2.2	2, 42
Product quality/safety	PR1	41-42
Product stewardship	EN26	33-35
Professional development	LA11	24-25
Public policy	SO5	46-47
Quality	PR1	41-42
Report coverage	3.1-3.4, 3.6-3.8, 3.10-3.12	IFC, 52, Index
Research policies	DMA-Society	5, 48
Research programs/goals	1.2	5-8
Safety performance	LA7	36-39, 52
Strategy	1.1, 1.2	1, 3
Supply chain		41
Toxic chemical use reduction	EN1	38, 52
Training	LA11	24-25, 35
Waste	EN22	34, 52
Water use	EN8	32, 52

Note: DMA – Disclosure on Management Approach